Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion's Aspira Labs Receives New York State Clinical Lab Permit

NEW YORK (GenomeWeb News) – Vermillion said today that its Aspira Labs subsidiary has received its clinical laboratory permit for the state of New York.

With the New York permit, Aspira is now licensed in all states requiring licensing, allowing the company to process Vermillion's OVA1 ovarian cancer test nationwide.

The permit also marks a milestone in the company's efforts to transition OVA1 testing from Quest Diagnostics to Aspira, which is a key aspect of its new commercial strategy.

"With the issuing of the New York state permit, Aspira Labs can now be responsible for all OVA1 processing in the US, which was a major goal in our new commercial agreement with Quest," Vermillion President and CEO Valerie Palmieri said in a statement.

Vermillion and Quest signed the new agreement in March, under which Vermillion will pay Quest an undisclosed sum and fees for logistical support services as Vermillion transitions its OVA1 ovarian cancer testing business from Quest to Aspira.